↠Research library / Recovery & tissue
BPC-157 is not currently legal to compound in the United States.
On July 23, 2026FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding it to the 503A bulks list. That vote is advisory and not binding, and adding a substance to the list requires a formal public rulemaking process that takes months to years. FDA has overruled the committee before, including in cases like this one, where its own scientists recommended against.
You are currently seeing a wave of sites announcing that BPC-157 is "legal now." It is not. We will update this page the day that changes, and not before.
BPC-157 is probably the single most-searched compound in this category, and almost everything written about it is published by someone selling it. We can't sell it to you, nobody legally can right now, so this page has no commercial angle. That's precisely why it's worth reading.
BPC-157 (Body Protection Compound-157) is a synthetic peptide of 15 amino acids, derived from a sequence identified in human gastric juice. Proposed mechanisms center on angiogenesis, growth factor modulation, and nitric oxide pathway effects, plausible mechanisms that would explain the animal findings.
The animal literature is genuinely extensive, covering tendon-to-bone healing, muscle and ligament injury, gastrointestinal protection, and more. It is also almost entirely rodent work.[2]
A 2026 narrative review of BPC-157 for musculoskeletal healing concluded that human research "remains limited to small pilot studies", in areas including musculoskeletal pain and interstitial cystitis, with no rigorous controlled trials validating efficacy.[1]
At the July 2026 advisory committee hearing, FDA staff reviewing the compound found limited evidence of effectiveness, resting on one small trial of 46 participants. The committee recommended it anyway, 8-6.[3]
The evidence does not support the confidence with which BPC-157 is marketed. It also does not refute the claims, the human data simply doesn't exist yet. Those are different statements, and most content on this compound collapses them in whichever direction suits the author.
Absence of evidence isn't evidence of absence. But it also isn't evidence of efficacy, and it's not a basis for injecting something.
| When | What happened |
|---|---|
| September 2023 | FDA placed BPC-157 in Category 2 of the 503A interim bulks guidance, significant safety risk. Compounding stopped. |
| September 2024 | Settlement with compounders: FDA agreed to halt unilateral action and submit key peptides to public PCAC review. |
| April 15, 2026 | FDA removed BPC-157 and 11 other peptides from Category 2 after nominators withdrew. Removal is not authorization. |
| July 23, 2026 | PCAC voted 8-6 to recommend adding BPC-157 to the 503A bulks list, over FDA scientists' objections. |
| Today | Still not legal to compound. Formal rulemaking must complete first. |
The same July meeting also recommended KPV, TB-500, MOTS-C, Semax, and Epitalon. Emideltide (DSIP) was the sole rejection, voted down 6-7.
Because it can't be obtained legally, essentially all BPC-157 in circulation comes from the gray market. That matters more here than almost anywhere:
See Safety & sourcing for why a purity certificate does not address this.
The panel recommended it. That's advisory. FDA must run a formal notice-and-comment rulemaking before anything is added to the 503A bulks list, which takes months at minimum. FDA also isn't bound by the recommendation and its own reviewers opposed it here.
Selling for genuine laboratory research is a different activity from selling to consumers who will inject it. When a site markets to consumers, provides dosing guidance, and labels "research use only," regulators have historically treated that label as evidence of knowledge rather than as a defense.
If FDA completes rulemaking and our pharmacy partner can compound it, and a provider judges it appropriate for a given patient, yes. Under the same evidence grading you see here. A Grade C compound stays labeled Grade C even when it becomes legal.
Written and published by third parties. Not affiliated with or endorsed by us.
Full library · Safety & sourcing ·
Regulatory status current as of the date shown. This area is changing quickly; we review this page monthly. [set review reminder]